Connect Biopharma Holdings Ltd (CNTB) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.88

From 52W high−75.62%

Volume1.01M

Market cap$56.66M

P/E (TTM)—

P/S (TTM)19.3x

Div yield—

Key dataOct 19, 2026

Open

$0.88

From 52W high

−75.62%

Volume

1.01M

Market cap

$56.66M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

P/E (TTM)

—

RSI (14)

32.2

MomentumView details →

1D Return

−0.72%

YTD Return

−68.38%

SummaryUpdated Jun 1, 2026

Connect Biopharma Holdings Limited (NASDAQ:CNTB) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Taicang, China. The company went public in March 2021 and focuses on discovering and developing immune modulators for treating serious autoimmune diseases and inflammatory conditions. Connect Biopharma operates in the highly specialized biotechnology sector, where companies typically spend years and hundreds of millions of dollars developing drug candidates through rigorous clinical trials before potentially bringing treatments to market.

Ask drillr about Connect Biopharma Holdings Ltd →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.5x

EV/Sales

8.8x

P/S (TTM)

19.3x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−1763.40%

EBITDA Margin

−1763.26%

ROE (TTM)

−192.81%

ROA (TTM)

−119.14%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

+293.70%

EPS YoY

−35.38%

FCF YoY

−10.92%

Revenue CAGR 3Y

−99.75%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−0.72%

YTD Return

−68.38%

1Y Return

−49.34%

RSI (14)

32.2

vs 50D SMA

−45.65%

vs 200D SMA

−60.53%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

2.37x

Quick Ratio

2.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.27

EPS Surprise

14.26%

Beats (12Q)

9/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

0.62%

Rev Surprise

269.69%

Financials snapshotView financials →

Revenue (TTM)

3.68M

Net Income (TTM)

−73.60M

Op. CF (TTM)

−71.35M

Next earningsNov 11, 2026 →

Latest newsMore news →

Connect Biopharma Holdings Limited reported positive topline results from its global Phase 2 study of a new COPD therapy, showing a significant drop in treatment failure.19d ago

Connect Biopharma Holdings Limited released topline results from its global Phase 2 study evaluating rademikibart, sending its stock to a 52-week low on Tuesday.34d ago

Similar companies

Tenax Therapeutics, Inc.TENX Fortress Biotech, Inc.FBIOP Pliant Therapeutics, Inc.PLRX Alps Group IncALPS Xilio Therapeutics, Inc.XLO Gain Therapeutics, Inc.GANX Find similar companies →

Latest newsMore news →

Connect Biopharma Holdings Limited reported positive topline results from its global Phase 2 study of a new COPD therapy, showing a significant drop in treatment failure.19d ago Connect Biopharma Holdings Limited released topline results from its global Phase 2 study evaluating rademikibart, sending its stock to a 52-week low on Tuesday.34d ago Connect Biopharma Holdings Limited reported financial results for the second quarter of 2026, ending June 30, 2026.68d ago